文献速递胃肠动力与功能性疾病

低FODMAP饮食联合β-半乳寡糖改善肠易激综合征症状但降低粪便双歧杆菌

β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

一项随机安慰剂对照三臂试验纳入69例Rome III成人IBS患者,比较假饮食加安慰剂、低FODMAP饮食加安慰剂、低FODMAP饮食加1.4 g/d β-半乳寡糖干预4周。结果显示低FODMAP饮食联合β-半乳寡糖组症状缓解率高于对照组,但未阻止双歧杆菌下降,且低FODMAP饮食降低粪便放线菌和丁酸。

要点

  • 低FODMAP饮食联合1.4 g/d β-半乳寡糖4周症状缓解率67%,高于对照30%。
  • 联合β-半乳寡糖未防止低FODMAP饮食引起的双歧杆菌下降。
  • 低FODMAP饮食降低粪便放线菌比例和丁酸,不建议严格长期使用。

核心结论

  • 低FODMAP饮食联合β-半乳寡糖比假饮食加安慰剂产生更高的症状缓解率,但添加1.4 g/d β-半乳寡糖未阻止双歧杆菌减少。
  • 低FODMAP饮食降低粪便放线菌和丁酸,因此不应建议严格长期使用。

研究设计与样本

  • 随机、安慰剂对照、三臂试验,纳入69例来自英国二级保健的Rome III成人IBS患者。
  • 患者随机接受假饮食加安慰剂(对照)、低FODMAP饮食加安慰剂(LFD)或低FODMAP饮食加1.4 g/d β-半乳寡糖(LFD/B-GOS)干预4周。

主要发现

  • 4周时LFD/B-GOS组症状充分缓解率为16/24(67%),高于对照组的7/23(30%)(OR 4.6,95%CI 1.3-15.6;P=0.015)。
  • 双歧杆菌浓度(log10 cells/g干重)在LFD与LFD/B-GOS组间无差异,但LFD/B-GOS组(9.49[0.73])低于对照组(9.77[0.41],P=0.018)。
  • 放线菌比例在LFD组(1.9%,P=0.003)和LFD/B-GOS组(1.8%,P<0.001)均低于对照组(4.2%)。
  • 粪便丁酸在LFD组(387.3,P=0.028)和LFD/B-GOS组(346.0,P=0.007)均低于对照组(609.2)。

临床怎么用

  • 对于IBS患者,低FODMAP饮食联合1.4 g/d β-半乳寡糖可考虑用于短期改善症状。
  • 应告知患者低FODMAP饮食可能降低双歧杆菌、放线菌和丁酸,避免严格长期使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The low FODMAP diet (LFD) reduces symptoms and bifidobacteria in irritable bowel syndrome (IBS). β-galactooligosaccharides (B-GOS) may reduce the symptoms and increase bifidobacteria in IBS. We investigated whether B-GOS supplementation alongside the LFD improves IBS symptoms while preventing the decline in bifidobacteria. METHODS: We performed a randomized, placebo-controlled, 3-arm trial of 69 Rome III adult patients with IBS from secondary care in the United Kingdom. Patients were randomized to a sham diet with placebo supplement (control) or LFD supplemented with either placebo (LFD) or 1.4 g/d B-GOS (LFD/B-GOS) for 4 weeks. Gastrointestinal symptoms, fecal microbiota (fluorescent in situ hybridization and 16S rRNA sequencing), fecal short-chain fatty acids (gas-liquid chromatography) and pH (probe), and urine metabolites (H NMR) were analyzed. RESULTS: At 4 weeks, adequate symptom relief was higher in the LFD/B-GOS group (16/24, 67%) than in the control group (7/23, 30%) (odds ratio 4.6, 95% confidence interval: 1.3-15.6; P = 0.015); Bifidobacterium concentrations (log10 cells/g dry weight) were not different between LFD and LFD/B-GOS but were lower in the LFD/B-GOS (9.49 [0.73]) than in the control (9.77 [0.41], P = 0.018). A proportion of Actinobacteria was lower in LFD (1.9%, P = 0.003) and LFD/B-GOS (1.8%, P < 0.001) groups than in the control group (4.2%). Fecal butyrate was lower in the LFD (387.3, P = 0.028) and LFD/B-GOS (346.0, P = 0.007) groups than in the control group (609.2). DISCUSSION: The LFD combined with B-GOS prebiotic produced a greater symptom response than the sham diet plus placebo, but addition of 1.4 g/d B-GOS did not prevent the reduction of bifidobacteria. The LFD reduces fecal Actinobacteria and butyrate thus strict long-term use should not be advised.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Wilson B, Rossi M, Kanno T, et al. β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. Am J Gastroenterol. 2020. PMID: 32433273. doi:10.14309/ajg.0000000000000641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。